Navigation Links
Biovail Concerned Shareholders Want Open Debate
Date:6/17/2008

Biovail CEO Refuses to Meet; Concerned Shareholders Believe It Reflects Unwillingness To Confront Issues and to Reveal His Inexperience and Lack of

Industry Knowledge

June 17 Conference Call with Analysts Available on BetterBiovail.com

All Shareholders Urged to See New Video and Vote Their YELLOW Proxy

TORONTO, June 17 /PRNewswire-FirstCall/ -- The Concerned Shareholders of Biovail Corporation (NYSE: BVF)(TSX: BVF) said today that a refusal by Biovail CEO William Wells to participate in a debate with Bruce Brydon, Concerned Shareholders' proposed CEO, sends a chilling message to Biovail shareholders.

"To make an informed vote, shareholders need a chance to evaluate each side," said a spokesman for The Concerned Shareholders. "Mr. Wells has limited experience in the pharmaceutical industry, and we believe his refusal to participate in a debate demonstrates is he is afraid to show -- one-on-one -- his lack of knowledge."

Mr. Wells's refusal to debate comes on the heels of an analysis by Glass Lewis & Co. that sharply criticizes the company and recommends a no-vote for all the company's nominees. The report also calls the appointment of Mr. Wells as CEO "inappropriate from a corporate governance standpoint" and suggests that there was an appearance of a conflict of interest in awarding lavish compensation packages to Mr. Wells and his predecessor at a time when the company is struggling financially.

"We believe Mr. Wells has limited knowledge of the industry and inadequate experience to run the company," the spokesman said. "But shareholders deserve to see his level of knowledge first hand -- face to face with Bruce Brydon, who has 30 years experience."

The Concerned Shareholders ask the incumbent Biovail Board and Mr. Wells to reconsider their stance and agree to the debate with Mr. Brydon.

"If they do not, we urge shareholders to take note of what this says," said the spokesman. "Do they want a Board and management team that is afraid to show shareholders what they know and what they don't know? Or do they want a Board and a leader who wants an open debate?"

All shareholders are urged to vote the YELLOW proxy in favour of the Concerned Shareholders slate of nominees. Copies of the proxy circular prepared by the Concerned Shareholders can be obtained via SEDAR (http://www.sedar.com) and http://www.betterbiovail.com or by contacting in Canada, Kingsdale Shareholder Services Inc. toll-free at 1-800-775-1986 or collect at 1-416-867-2272, or in the United States, Innisfree M&A Incorporated toll-free at 1-877-717-3929.

Certain statements contained in this release constitute forward-looking statements. The words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Concerned Shareholders, the Concerned Shareholders' nominees, the Company or its current or future management, are intended to identify forward-looking statements. Such statements reflect the Concerned Shareholders' or the Concerned Shareholders' nominees' current views with respect to future events and are subject to certain risks, uncertainties and assumptions. The Concerned Shareholders' nominees assume no responsibility for any such statements. Many factors could cause the company's actual results, performance or achievements that may be expressed or implied by such forward- looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include, but are not limited to, economic, business, technological, competitive and regulatory factors.


'/>"/>
SOURCE Bruce Brydon
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
2. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
3. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
4. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
5. Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value
6. Spherix Holds Annual Shareholders Meeting
7. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
8. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
9. Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
10. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
11. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... for pharmaceutical research and development (R&D), today announced the launch of ... and interpretation for the rapidly evolving field of precision medicine. , ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... and scientists from around the world, was today awarded the "Best Science & ... based entirely on merit and decided upon by a dedicated team of researchers ...
(Date:1/19/2017)... NEW YORK , Jan. 18, 2017 /PRNewswire/ ... expected to reach USD 92.9 billion by 2025, ... Research, Inc. Pharmaceutical industry has been adaptive of ... functions as early as 2002. Among the services ... the forerunners. For instance, Johnson & Johnson was ...
Breaking Biology Technology:
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
Breaking Biology News(10 mins):